BioAge Labs Statistics
Total Valuation
BioAge Labs has a market cap or net worth of $798.72 million. The enterprise value is $417.88 million.
Important Dates
The last earnings date was Friday, May 8, 2026, before market open.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioAge Labs has 44.40 million shares outstanding. The number of shares has increased by 95.07% in one year.
| Current Share Class | 44.40M |
| Shares Outstanding | 44.40M |
| Shares Change (YoY) | +95.07% |
| Shares Change (QoQ) | +17.41% |
| Owned by Insiders (%) | 2.45% |
| Owned by Institutions (%) | 56.96% |
| Float | 37.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 77.43 |
| Forward PS | 7.81 |
| PB Ratio | 2.11 |
| P/TBV Ratio | 2.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 40.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 24.76, with a Debt / Equity ratio of 0.01.
| Current Ratio | 24.76 |
| Quick Ratio | 24.26 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -211.45 |
Financial Efficiency
Return on equity (ROE) is -25.98% and return on invested capital (ROIC) is -17.99%.
| Return on Equity (ROE) | -25.98% |
| Return on Assets (ROA) | -17.15% |
| Return on Invested Capital (ROIC) | -17.99% |
| Return on Capital Employed (ROCE) | -26.64% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $166,387 |
| Profits Per Employee | -$1.45M |
| Employee Count | 62 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +343.10% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +343.10% |
| 50-Day Moving Average | 18.34 |
| 200-Day Moving Average | 12.21 |
| Relative Strength Index (RSI) | 52.12 |
| Average Volume (20 Days) | 395,244 |
Short Selling Information
The latest short interest is 1.75 million, so 3.93% of the outstanding shares have been sold short.
| Short Interest | 1.75M |
| Short Previous Month | 1.56M |
| Short % of Shares Out | 3.93% |
| Short % of Float | 4.71% |
| Short Ratio (days to cover) | 3.27 |
Income Statement
In the last 12 months, BioAge Labs had revenue of $10.32 million and -$89.93 million in losses. Loss per share was -$2.39.
| Revenue | 10.32M |
| Gross Profit | -63.65M |
| Operating Income | -101.71M |
| Pretax Income | -89.93M |
| Net Income | -89.93M |
| EBITDA | -101.47M |
| EBIT | -101.71M |
| Loss Per Share | -$2.39 |
Full Income StatementBalance Sheet
The company has $383.19 million in cash and $4.03 million in debt, with a net cash position of $380.84 million or $8.58 per share.
| Cash & Cash Equivalents | 383.19M |
| Total Debt | 4.03M |
| Net Cash | 380.84M |
| Net Cash Per Share | $8.58 |
| Equity (Book Value) | 379.12M |
| Book Value Per Share | 8.54 |
| Working Capital | 376.03M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$88.31 million and capital expenditures -$319,000, giving a free cash flow of -$88.63 million.
| Operating Cash Flow | -88.31M |
| Capital Expenditures | -319,000 |
| Depreciation & Amortization | 239,000 |
| Net Borrowing | -6.00M |
| Free Cash Flow | -88.63M |
| FCF Per Share | -$2.00 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -985.93% |
| Pretax Margin | -871.75% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioAge Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -95.07% |
| Shareholder Yield | -95.07% |
| Earnings Yield | -11.26% |
| FCF Yield | -11.10% |
Analyst Forecast
The average price target for BioAge Labs is $51.50, which is 186.27% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $51.50 |
| Price Target Difference | 186.27% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 47.02% |
| EPS Growth Forecast (5Y) | -8.30% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |
